Transl Clin Pharmacol.  2017 Jun;25(2):53-58. 10.12793/tcp.2017.25.2.53.

The stable isotope method for determining absolute bioavailability

• Atkinson A

• KMID: 2386760
• DOI: http://doi.org/10.12793/tcp.2017.25.2.53

Abstract

The bioavailability of a drug is usually assessed in healthy subjects. However, it is reasonable to expect that significant alterations in bioavailability may occur in actual patients with different diseases or in individuals belonging to special populations. Relatively few studies have been conducted to examine this possibility. The stable isotope method is well suited to compare absolute bioavailability in patients and healthy subjects. Studies in which this method was used indicate that significant changes in the bioavailability of some drugs are particularly likely in patients with advanced liver disease and in those whose splanchnic blood flow is reduced. The expectation is that bioavailability in neonates, children, and pregnant women may also differ from that in non-pregnant adults.

Keyword

Pharmacokinetics; Stable isotopes; Absolute bioavailability; Patient studies

MeSH Terms

Adult
Biological Availability*
Child
Female
Healthy Volunteers
Humans
Infant, Newborn
Liver Diseases
Methods*
Pharmacokinetics
Pregnant Women

Figure

• 

  Figure 1 Relationship between bioavailability and CLF as an indirect indicator of splanchnic blood flow. Absorption of NAPA was reduced in both healthy subjects (■) and patients (■) with CLF less than 1.1 L/min (p = .0286, Fisher's exact test). (Data from Strong et al. (2) and Atkinson et al. (20)).

Reference

1. CDER. Draft Guidance for Industry. Bioavailability and bioequivalence studies submitted in NDAs or INDs - general; considerations. Silver Spring, MD: FDA;03. 2014. Accessed 1 December 2016. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM389370.pdf.

2. Strong JM, Dutcher JS, Lee WK, Atkinson AJ Jr. Absolute bioavailability of N-acetylprocainamide determined by a novel stable isotope method. Clin Pharmacol Ther. 1975; 18:613–622.

3. Aston FW. Untitled announcement. Science. 1919; 104:134.

4. Schoenheimer R, Rittenberg D. Deuterium as an indicator in the study of intermediary metabolism. J Biol Chem. 1935; 111:163–168.

5. Maynert EW, Van Dyke HB. The metabolic fate of pentobarbital. Isotope dilution experiments with urine after the administration of labeled pentobarbital. J Pharmacol Exp Ther. 1950; 98:174–179.

6. Gohlke RS, McLafferty FW. Early gas chromatography/mass spectrometry. J Am Soc Mass Spectrom. 1993; 4:367–371.

7. Ryhage R. Use of a mass spectrometer as a detector and analyzer for effluents emerging from high temperature gas liquid chromatography columns. Anal Chem. 1964; 36:759–764.

8. Hammar CG, Holmstedt B, Ryhage R. Mass fragmentography. Identification of chrolopromazine and its metabolites in human blood by a new method. Anal Biochem. 1968; 25:532–548.

9. Strong JM, Atkinson AJ Jr. Simultaneous measurement of plasma concentrations of lidocaine and its desethylated metabolite by mass fragmentography. Anal Chem. 1972; 44:2287–2290.

10. Bode H, Brendel E, Ahr G, Fahr U, Harder S, Staib AH. Investigation of nifedipine absorption in different regions of the human gastrointestinal (GI) tract after simultaneous administration of 13C- and 12C-nifedipine. Eur J Clin Pharmacol. 1996; 50:195–201.

11. Glaeser H, Drescher S, Hofmann U, Heinkele G, Somogyi AA, Eichelbaum M, et al. Impact of concentration and rate of intraluminal drug delivery on absorption and gut wall metabolism of verapamil in humans. Clin Pharmacol Ther. 2004; 76:230–238.

12. Sun JX, Piraino AJ, Morgan JM, Joshi JC, Cipriano A, Chan K, et al. Comparative pharmacokinetics and bioavailability of nitroglycerin and its metabolites from Transderm-Nitro, Nitrodisc, and Nitro-Dur II systems using a stable isotope technique. J Clin Pharmacol. 1995; 35:390–397.

13. Aliwarga T, Cloyd JC, Goel V, Brundage RC, Marino SE, Leppik IE, et al. Excretion of the principal urinary metabolites of phenytoin and absolute oral bioavailability determined by use of a stable isotope in patients with epilepsy. Ther Drug Monit. 2011; 33:56–63.

14. Vogelgesang B, Echizen H, Schmidt E, Eichelbaum M. Stereoselective first-pass metabolism of highly cleared drugs: studies of the bioavailability of L- and D-verapamil examined with a stable isotope technique. Br J Clin Pharmacol. 1984; 18:733–740.

15. Dilger K, Eckhardt K, Hofmann U, Kucher K, Mikus G, Eichelbaum M. Chronopharmacology of intravenous and oral modified release verapamil. Br J Clin Pharmacol. 1999; 47:413–419.

16. Somogyi A, Albrecht M, Kliems G, Schäfer K, Eichelbaum M. Pharmacokinetics, bioavailability and ECG response of verapamil in patients with liver cirrhosis. Br J Clin Pharmacol. 1981; 12:51–60.

17. Aronoff G, Brier M, Mayer ML, Barbalas M, Aogaichi K, Sloan R, et al. Bioavailability and kinetics of cibenzoline in patients with normal and impaired renal function. J Clin Pharmacol. 1991; 31:38–44.

18. Mikus G, Mast V, Fischer C, Machleidt C, Kuhlmann U, Eichelbaum M. Pharmacokinetics, bioavailability, metabolism and acute and chronic antihypertensive effects of nitrendipine in patients with chronic renal failure and moderate to severe hypertension. Br J Clin Pharmacol. 1991; 31:313–322.

19. Mikus G, Fischer C, Heuer B, Langen C, Eichelbaum M. Application of stable isotope methodology to study the pharmacokinetics, bioavailability, and metabolism of nitrendipine after i.v. and p.o. administration. Br J Clin Pharmacol. 1987; 24:561–569.

20. Atkinson AJ Jr, Ruo TI, Pierges AA, Breiter HC, Connelly TJ, Sedek GS, et al. Pharmacokinetics of N-acetylprocainamide in patients profiled with a stable isotope method. Clin Pharmacol Ther. 1989; 46:182–189.

21. Kasuya Y, Mamada K, Baba S, Matsukura M. Stable-isotope methodology for the bioavailability study of phenytoin during multiple-dosing regimens. J Pharm Sci. 2985; 74:503–507.

22. Meresaar U, Nilsson MI, Holmstrand J, Änggård E. Single dose pharmacokinetics and bioavailability of methadone in man studied with a stable isotope method. Eur J Clin Pharmacol. 1981; 20:473–478.

23. Beaver WT, Wallenstein SL, Houde RW, Rogers A. A clinical comparison of the analgesic effects of methadone and morphine administered intramuscularly, and of orally and parenterally administered methadone. Clin Pharmacol Ther. 1967; 8:415–426.

24. Fromm MF, Dilger K, Busse D, Kroemer HK, Eichelbaum M, Klotz U. Gut wall metabolism of verapamil in older people: effects of rifampin-mediated enzyme induction. Br J Clin Pharmacol. 1998; 45:247–255.

25. Fromm MF, Busse D, Kroemer HK, Eichelbaum M. Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin. Hepatology. 1996; 24:796–801.

26. Dilger K, Hofmann U, Klotz U. Enzyme induction in the elderly: Effect of rifampin on the pharmacokinetics and pharmacodynamics of propafenone. Clin Pharmacol Ther. 2000; 67:512–520.

27. Dilger K, Greiner B, Fromm MF, Hofmann U, Kroemer HK, Eichelbaum M. Consequences of rifampin treatment on propafenone disposition in extensive and poor metabolizers of CYP2D6. Pharmacogenetics. 1999; 9:551–559.

28. Malik SI, Painter MJ, Venkataramanan R, Alvin JD. Phenytoin and phenobarbital stable isotope studies in neonates. Pediatr Neurol. 2003; 29:376–380.

29. Roth DE, Pezzack B, Al Mahmud A, Abrams SA, Islam M, Aimone Phillips A, et al. Bioavailability of enteric-coated microencapsulated calcium during pregnancy: a randomized crossover trial in Bangladesh. Am J Clin Nutr. 2014; 100:1587–1595.

30. Eichelbaum M, von Unruh GE, Somogyi A. Application of stable isotope labeled drugs in clinical pharmacokinetic investigations. Clin Pharmacokinet. 1982; 7:490–507.

31. Heck HA, Buttrill SE Jr, Flynn NW, Dyer RL, Anbar M, Cairns T, et al. Bioavailability of imipramine tablets relative to a stable isotope-labeled internal standard: Increasing the power of bioavailability tests. J Pharmacokinet Biopharm. 1979; 7:233–248.

32. Browne TR. Stable isotopes in clinical pharmacokinetic investigations: advantages and disadvantages. Clin Pharmacokinet. 1990; 18:423–433.

33. Browne TR. Stable isotope techniques in early drug development: an economic evaluation. J Clin Pharmacol. 1998; 38:213–220.

34. Blake MI, Crespi HL, Katz JJ. Studies with deuterated drugs. J Pharm Sci. 1975; 64:367–391.

35. Wolen RL. The application of stable isotopes to studies of drug bioavailability and bioequivalence. J Clin Pharmacol. 1986; 26:419–424.

36. Dutcher JS, Strong JM, Lee W-K, Atkinson AJ Jr. Stable isotope methods for pharmacokinetic studies in man. In : Klein R, editor. Proceedings of the Second International Conference on Stable Isotopes. Washington, DC: US Govt Printing Office;1976. (CONF-751027).

37. Klein PD, Klein ER. Stable isotopes: origins and safety. J Clin Pharmacol. 1986; 26:378–382.

38. CDER. Guidance for Clinical Investigators, Sponsors, and IRB's. Investigational new drug applications -(INDS) - determining whether human research studies can be conducted without an IND. Rockville, MD: FDA;09. 2013. Accessed 1 December 2016. http://www.fda.gov/downloads/drugs/guidances/ucm229175.pdf.

39. CDER, CBER. Guidance for industry. Pharmacokinetics in patients with impaired hepatic function: study design, data analysis, and impact on dosing and labeling. Rockville, MD: FDA;05. 2003. Accessed 1 December 2016. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072123.pdf.

40. Koch-Weser J. Pharmacokinetics of procainamide. Ann N Y Acad Sci. 1971; 179:370–382.

41. Crouthamel WG, Diamond L, Dittert LW, Dolusio JT. Drug absorption VII: influence of mesenteric blood flow on intestinal drug absorption in dogs. J Pharm Sci. 1975; 64:664–671.

42. Samardzic J, Turner MA, Bax R, Allegaert K. Neonatal medicines research: challenges and opportunities. Expert Opin Drug Metab Toxicol. 2015; 11:1041–1052.